Click here for Product Information

________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

For patients living with chronic heart failure, time is essential, so start with ENTRESTO (sacubitril/valsartan)1–3

 

Icon of a person with a medicine bottle, with text underneath 'and for previously diagnosed patients who are ACEi/ARB-naive'

For patients living with heart failure
in place of an ACEi or an ARB1,2 5-14

 

 

 Image of a heart with 'Even when patients do not exhibit apparent symptoms, cardiac damage is constantly occurring' - Burden of heart failure , text next to it.

Even when patients do not exhibit apparent symptoms, cardiac damage is constantly occurring4

 
 

Image of a heart with 'ENTRESTO has a dual MoA that simultaneously inhibits vasoconstriction and promotes vasodilation', text next to it - mode of action.

ENTRESTO has a dual MoA that simultaneously inhibits vasoconstriction and promotes vasodilation5

 
 

Image of a hospital with 'Change the disease trajectory in chronic HFrEF' text next to it - disease trajectory.

Change the disease trajectory in chronic HFrEF‌1,2,5–14

 
 

Image of a graph with 'Improve the chronic HFrEF patient’s experience vs ACEi (enalapril)' text next to it - Improvements in quality of life.

Improve the chronic HFrEF patient’s experience vs ACEi (enalapril)7,10

 
 

Image of a shield with 'National guidelines support ENTRESTO as a 1st line treatment option in chronic HFrEF' text next to it - guidelines.

Guidelines support ENTRESTO as a 1st line treatment option in chronic HFrEF 1,2*

 
 

 

ENTRESTO is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.

* Local reimbursement criteria apply

ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; HFrEF, heart failure with reduced ejection fraction; MoA, mode of action.

References:

  1. European Heart Journal (2021) 42, 35993726 ESC GUIDELINES doi:10.1093/eurheartj/ehab368
  2. Maddox TM, et al. J Am Coll Cardiol 2021;77(6):772–810.
  3. Ponikowski P, et al. ESC Heart Fail 2014;1(1):4–25.
  4. Mann DL, Bristow MR. Circulation 2005;111(21):2837–2849.
  5. ENTRESTO Summary of Product Characteristics. Accessed December 2021 at www.medicines.ie
  6. Claggett B, et al. N Engl J Med 2015;373(23):2289–2290.
  7. Lewis EF, et al. Circ Heart Fail 2017;10(8):e003430.
  8. McMurray JJ, et al. N Engl J Med 2014;371:993–1004.
  9. Solomon SD, et al. JACC Heart Fail 2016;4(10):816–822.
  10. Chandra A, et al. JAMA Cardiol 2018;3(6):498–505.
  11. Velazquez EJ, et al. N Engl J Med 2019;380(6):539–548.
  12. Desai AS, et al. JAMA 2019;322(11):1077–1084.
  13. Wachter R, et al. Eur J Heart Fail 2019;21(8):998–1007.
  14. Januzzi JL Jr, et al. JAMA 2019;322(11):1085–1095.
April 2022 | IE 171966

Reporting of side effects
Adverse events (side effects) can be reported via the HPRA. Reporting forms and information can be found at https://www.hpra.ie/homepage/about-us/report-an-issue. Adverse events could also be reported to Novartis preferably via www.report.novartis.com or by email: [email protected] or by calling (01) 2080 612. For information on any of our medicinal products please contact Medical Information on (01) 260 1255.

×

Ask Speakers

×

Medical Information Request